Company intelligence / Profile preview

Araim Pharmaceuticals

Tarrytown, New York, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Other

Overview

Araim Pharmaceuticals has conducted multiple Phase 2 clinical trials for its lead compound Cibinetide (formerly ARA 290), an 11-amino acid peptide that activates the Innate Repair Receptors. Clinical trials have shown Cibinetide can increase small nerve fiber abundance in the cornea and skin, suggesting a disease-modifying effect. The company has completed or terminated several Phase 2 trials for conditions including diabetic macular edema, small fiber neuropathy, and sarcoidosis.

Therapeutic areas: NeurologyPsychiatryOphthalmologyEndocrinologyImmunology
Modalities: Peptides
Industry: Biotech

Drug pipeline

1 asset

cibinetide

Partnerships

Karolinska InstituteNational Institute on AgingQueens University Belfast

Beyond the preview

Go deeper on Araim Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Araim Pharmaceuticals.

Explore the full profile